Strides Pharma's Stabilization of Balance Sheet Paves Way for International Growth

Strides Pharma Science: Navigating Growth Through Diversification and Acquisitions

FY26 Financial Highlights

• Rs 1,435.8 crore in reported net debt as of Q3FY26
• Net debt to EBITDA (Earnings before interest, taxes, depreciation and amortisation) at 1.6x and net debt to equity at 0.5x, representing a reduction of more than 50% from FY23
• Rs 484 crore in operating cash flow for the nine months ended December 31
• Rs 3,535.2 crore in revenue for 9MFY26, up 4.7% YoY
• EBITDA margin of 19.4%

Business Strategy

Read also: SpaceX Seeks Record $75 Billion IPO, Potentially Positioning Elon Musk as the World's First Trillionaire

Strides Pharma Science is shifting its focus towards the next phase of growth, building on the strength of its US business while pushing deeper into non-US markets through targeted acquisitions and partnerships. The company aims to invest selectively without stretching its finances, driven by a renewed focus on diversification and risk management.

US Business

The US remains the mainstay of Strides' business, accounting for around 52% of FY26 revenue. The company has consistently delivered strong results, with market-leading positions across more than half its portfolio. The business is profitable and sustainable, with a focus on chronic therapies to improve earnings stability and reduce vulnerability to sudden demand shocks.

Ex-US Markets

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Strides is increasingly leaning on ex-US markets to drive incremental growth, with a diversified footprint across the UK, Europe, Australia, South Africa, and parts of Africa. The company has built a relatively balanced contributions across regions, with a recent acquisition of select Sandoz assets in Africa expected to generate revenue in the mid-$50 million range with a potential compound annual growth rate of 14-15% over the next few years.

M&A Strategy

The management remains cautious about deal-making, stressing that acquisitions will remain closely aligned to Strides' existing strengths. The company is not looking to enter completely new or unrelated segments, instead focusing on building on its existing capabilities - manufacturing, regulatory, and commercial. Recent collaboration activity has centred on R&D-led areas, such as respiratory therapies, reflecting a preference for adjacent expansion rather than high-risk diversification.